AI model aims to personalize esophageal cancer care
NCT ID NCT07354295
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether an artificial intelligence (AI) system can predict how well esophageal cancer will respond to treatment and estimate a patient's long-term outlook. Researchers will collect medical images, genetic data, and other health information from 1,500 participants to train the AI model. The goal is to help doctors choose the best therapy for each person, but this study does not test a new treatment itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2025
- Expected to finish
-
Sep 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients diagnosed with esophgeal cancer and have received treatment in Tongji hospital
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Histopathologically diagnosed esophageal cancer 2. Complete baseline clinical data available (including demographic characteristics, ECOG performance score, TNM staging, etc.) 3. No other primary malignant tumors 4. Provision of informed consent 5. Availability of pre-treatment CT imaging Exclusion Criteria: 1. Imaging data quality insufficient for analysis 2. Presence of another primary malignant tumor 3. Severe systemic disease
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Tongji hospital, Tongji medical college, Huazhong university of science and technology
RECRUITINGWuhan, Other (Non U.s.), 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Can a guided missile for chemo hit tumors harder and spare healthy tissue?
- Can a new drug shrink tumors that resist standard care?